Open Access Open Access  Restricted Access Subscription or Fee Access

The interagency strategic plan for research and development of blood products and related technologies for trauma care and emergency preparedness 2015-2020

Anthony E. Pusateri, PhD, Mary J. Homer, PhD, Todd E. Rasmussen, MD, Kevin R. Kupferer, DHSc, W. Keith Hoots, MD

Abstract


Intensive blood use is expected to occur at levels, which will overwhelm blood supplies as they exist with current capabilities and technologies, both in civilian mass casualty events and military battlefield trauma. New technologies are needed for trauma care, and specifically to provide safer, more effective, and more logistically supportable blood products to treat patients with, or at risk of developing, acquired bleeding disorders resulting from trauma, acute radiation exposure, or other causes. Three of the primary agencies with major research and development programs related to blood products, the Biomedical Advanced Research and Development Authority (BARDA), the Department of Defense (DoD), and the National Heart, Lung, and Blood Institute are uniquely positioned to partner in addressing these issues, which have significant implications for each respective agency, as well as for the US population. Providing leadership, coordination, and oversight for the Food and Drug Administration’s national and global health security, counterterrorism, and emerging threats portfolios, the US Food and Drug Administration Office of Counterterrorism and Emerging Threats serves in a critical advisory and facilitative role regarding development and availability of blood products. This plan is informed by the 2012 PHEMCE Strategy (US Department of Health and Human Services, 2012), the 2007 “Shaping the Future of Research” Strategic Plan for the National Heart, Lung, and Blood Institute, the 2011 BARDA Strategic Plan, the DoD Combat Casualty Care Research Program: Policy Review, the 2015 DoD Hemorrhage and Resuscitation Research and Development Strategic Plan, and more than 30 participants from other agencies who participated in planning.


Keywords


research and development, blood product, Interagency

Full Text:

PDF

References


US Department of Health and Human Services: Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) strategy. Washington, DC: US Government Printing Office, 2012.

US Government Accountability Office: INTERAGENCY COLLABORATION: Key Issues for Congressional Oversight of National Security Strategies, Organizations, Workforce, and Information Sharing. Washington, DC: US Government Printing Office, 2009. GAO-09-904SP.

US Department of Health and Human Services: Shaping the Future of Research - A Strategic Plan for the National Heart, Lung, and Blood Institute. Washington, DC: US Government Printing Office, 2007. NIH Publication No. 07-6150.

US Department of Health and Human Services: Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan 2011-2016. Washington, DC: US Government Printing Office, 2011.

US Government Accountability Office: DEFENSE HEALTH: Actions Needed to Ensure Combat Casualty Care Research Achieves Goals. Washington, DC: US Government Printing Office, 2013. GAO-13-209.

US Department of Defense: Combat Casualty Care Research Program: Policy Review. Fort Detrick, MD: US Department of Defense, 2015.

US Department of Defense: DoD Hemorrhage and Resuscitation Research Program 2015-2020 Strategic Plan. Fort Detrick, MD: US Department of Defense, 2015.

Pusateri AE, Dubick MA: The US Department of Defense Hemorrhage and Resuscitation Research and Development Program. Shock. 2015; 44(suppl 1): 3-5.

Eastridge BJ, Mabry RL, Seguin P, et al.: Death on the battlefield (2001–2011): Implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012; 73(6): S431-S437.

US Department of Defense: Initial Capabilities Document for Department of Defense (DoD) Combat Casualty Care Medical Research and Development. Washington, DC: US Department of Defense, 2015.

Pusateri AE, Given MB, Macdonald VW, et al.: Comprehensive US government program for dried plasma development. Transfusion. 2016; 56(1): S16-S23.




DOI: http://dx.doi.org/10.5055/ajdm.2018.0299

Refbacks

  • There are currently no refbacks.
This site uses cookies to maintain session information critical to the user's experience and environment on this system. Click "Accept Cookies" to continue.
For more details please visit our privacy statement at: Privacy & GDPR